Comparative assessment of a DNA and protein Leishmania donovani gamma glutamyl cysteine synthetase vaccine to cross-protect against murine cutaneous leishmaniasis caused by L. major or L. mexicana infection

Vaccine

Volumn 30, Issue 7, 2012, Pages 1357-1363

  Campbell, S A ^a   Alawa, J ^b   Doro, B ^c   Henriquez, F L ^d   Roberts, C W ^c   Nok, A ^b   Alawa, C B I ^b   Alsaadi, M ^c   Mullen, A B ^c   Carter, K C ^c  

^a EDINBURGH NAPIER UNIVERSITY   (United Kingdom)

^b AHMADU BELLO UNIVERSITY   (Nigeria)

^c UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^d UNIVERSITY OF THE WEST OF SCOTLAND   (United Kingdom)

Author keywords

Gamma glutamyl cysteine synthetase; Leishmania; Vaccine

Indexed keywords

DNA VACCINE; GLUTAMATE CYSTEINE LIGASE; LEISHMANIA DONOVANI GAMMA GLUTAMYL CYSTEINE SYNTHETASE VACCINE; LEISHMANIA VACCINE; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY SPECIFICITY; ANTIBODY TITER; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CROSS PROTECTION; DNA IMMUNIZATION; FEMALE; GENE SEQUENCE; GENE VECTOR; IMMUNE RESPONSE; LEISHMANIA DONOVANI; LEISHMANIA MAJOR; LEISHMANIA MEXICANA; MALE; MOUSE; NONHUMAN; PARASITE IMMUNITY; PRIORITY JOURNAL; SKIN LEISHMANIASIS;

ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; CROSS PROTECTION; EPITOPES; GLUTAMATE-CYSTEINE LIGASE; HUMANS; LEISHMANIA DONOVANI; LEISHMANIA MAJOR; LEISHMANIA MEXICANA; LEISHMANIASIS VACCINES; LEISHMANIASIS, CUTANEOUS; LEISHMANIASIS, VISCERAL; MICE; MICE, INBRED BALB C; RECOMBINANT PROTEINS; VACCINATION; VACCINES, DNA; VACCINES, SUBUNIT;

EID: 84856572518     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.12.067     Document Type: Article

References (22)

1. Ezra N., Ochoa M.T., Craft N. Human immunodeficiency virus and leishmaniasis. J Glob Infect Dis 2010, 2:248-257.
2. Goto Y., Bhatia A., Raman V.S., Vidal S.E., Bertholet S., Coler R.N., et al. Leishmania infantum sterol 24-c-methyltransferase formulated with MPL-SE induces cross-protection against L. major infection. Vaccine 2009, 27:2884-2890.
3. Moore E.M., Lockwood D.N. Treatment of visceral leishmaniasis. J Glob Infect Dis 2010, 2:151-158.
4. Kedzierski L. Leishmaniasis vaccine: where are we today?. J Glob Infect Dis 2010, 2:177-185.
5. Gradoni L., Foglia Manzillo V., Pagano A., Piantedosi D., De Luna R., Gramiccia M., et al. Failure of a multi-subunit recombinant leishmanial vaccine (MML) to protect dogs from Leishmania infantum infection and to prevent disease progression in infected animals. Vaccine 2005, 23:5245-5251.
6. Miret J., Nascimento E., Sampaio W., Franca J.C., Fujiwara R.T., Vale A., et al. Evaluation of an immunochemotherapeutic protocol constituted of N-methyl meglumine antimoniate (Glucantime) and the recombinant Leish-110f+MPL-SE vaccine to treat canine visceral leishmaniasis. Vaccine 2008, 26:1585-1594.
7. Trigo J., Abbehusen M., Netto E.M., Nakatani M., Pedral-Sampaio G., de Jesus R.S., et al. Treatment of canine visceral leishmaniasis by the vaccine Leish-111f+MPL-SE.2. Vaccine 2010, 28:3333-3340.
8. Henriquez F.L., Campbell S.A., Roberts C.W., Mullen A.B., Burchmore R., Carter K.C. Vaccination with recombinant Leishmania donovani gamma-glutamylcysteine synthetase fusion protein protects against L. donovani infection. J Parasitol 2010, 96:929-936.
9. Carter K.C., Henriquez F.L., Campbell S.A., Roberts C.W., Nok A., Mullen A.B., et al. DNA vaccination against the parasite enzyme gamma-glutamylcysteine synthetase confers protection against Leishmania donovani infection. Vaccine 2007, 25:4502-4509.
10. Chenna R., Sugawara H., Koike T., Lopez R., Gibson T.J., Higgins D.G., Thompson J.D. Multiple sequence alignment with the Clustal series of programs. Nucleic Acids Res 2003, 31:3497-3500.
11. Bhaumik S., Basu R., Sen S., Naskar K., Roy S. KMP-11 DNA immunization significantly protects against L. donovani infection but requires exogenous IL-12 as an adjuvant for comparable protection against L. major. Vaccine 2009, 27:1306-1316.
12. Sharma P., Gurumurthy S., Duncan R., Nakhasi H.L., Salotra P. Comparative in vivo expression of amastigote up regulated Leishmania genes in three different forms of Leishmaniasis. Parasitol Int 2010, 59:262-264.
13. Rochette A., Raymond F., Ubeda J.M., Smith M., Messier N., Boisvert S., et al. Genome-wide gene expression profiling analysis of Leishmania major and Leishmania infantum developmental stages reveals substantial differences between the two species. BMC Genomics 2008, 9:255-270.
14. Mosmann T.R., Coffman R.L. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989, 7:145-173.
15. Hünig T., Lühder F., Elflein K., Gogishvili T., Fröhlich M., Guler R., et al. Brombacher F.CD28 and IL-4: two heavyweights controlling the balance between immunity and inflammation. Med Microbiol Immunol 2010, 199:239-246.
16. Sosa M.R., Rosas L.E., McKenzie A.N., Satoskar A.R. IL-13 gene-deficient mice are susceptible to cutaneous L. mexicana infection. Eur J Immunol 2001, 31:3255-3260.
17. Bryson K.J., Millington O.R., Mokgethi T., McGachy H.A., Brombacher F., Alexander J. BALB/c mice deficient in CD4 T cell IL-4Rα expression control Leishmania mexicana load although female but not male mice develop a healer phenotype. PLoS Negl Trop Dis 2011, 4(5):e930.
18. Aguilar-Be I., da Silva Zardo R., Paraguai de Souza E., Borja-Cabrera G.P., Rosado-Vallado M., Mut-Martin M., et al. Cross-protective efficacy of a prophylactic Leishmania donovani DNA vaccine against visceral and cutaneous murine leishmaniasis. Infect Immun 2005, 73:812-819.
19. Liew F.Y., Xu D., Chan W.L. Immune effector mechanism in parasitic infections. Immunol Lett 1999, 65:101-104.
20. Etges R., Müller I. Progressive disease or protective immunity to Leishmania major infection: the result of a network of stimulatory and inhibitory interactions. J Mol Med (Berl) 1998, 76:372-390.
21. Daneshvar H., Coombs G.H., Hagan P., Phillips R.S. Leishmania mexicana and Leishmania major: attenuation of wild-type parasites and vaccination with the attenuated lines. J Infect Dis 2003, 187:1662-1668.
22. Ivory C., Chadee K. DNA vaccines: designing strategies against parasitic infections. Genet Vaccines Ther 2004, 2:17-21.